Learning Objectives
Upon completion of this activity, participants should be able to:
- Apply proteasome inhibitors in the clinical management of patients with relapsed/refractory mantle cell lymphoma
- Contrast stem cell transplantation strategies in the treatment of relapsed/refractory mantle cell lymphoma
- Discuss current data on second-line treatment strategies for patients with relapsed/refractory mantle cell lymphoma
- Interpret results of clinical trials that evaluate the use of investigational agents for the treatment of mantle cell lymphoma
Topics covered include:
- Introduction
- Single-Agent Bortezomib in the Treatment of Mantle Cell Lymphoma
- Bendamustine in the Treatment of Mantle Cell Lymphoma
- Stem Cell Transplantation in Relapsed Mantle Cell Lymphoma
- Immunomodulation With Thalidomide and Lenalidomide in Relapsed Mantle Cell Lymphoma
- mTOR Inhibition With Temsirolimus
- Other Treatment Approaches for Mantle Cell Lymphoma
- Conclusion
Abstract